Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of DP303c in HER2-positive unresectable locally advanced, recurrent, or metastatic breast cancer
CTR20220664Phase 2Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DP303c in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2022; status: completed.
02
Drugs
DP303c
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20220664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220664.